Saturday 15 November 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Polish Health Minister quits over pharma links

Polish Health Minister quits over pharma links

10 December 2007

Poland's recently-elected government has been tested by the sudden resignation of the Deputy Health Minister after allegations emerged that he might be involved in corrupt payments from drug firms. The Polish Prime Minister, Donald Tusk (Civic Platform), who only took office on November 11 following parliamentary elections in October, accepted the resignation of Boleslaw Piecha (Law and Justice, PiS). The issue is complicated by the fact that the two are members of different coalition parties in the center and center-right government.

Mr Piecha was the subject of local media allegations that he had held private meetings with representatives from pharmaceutical companies to discuss the adoption of new products on the list of state-reimbursed drugs, the UPI news agency reports.

The Polish Dziennik daily newspaper in particular alleged that the disgraced deputy minister had added "an expensive medicine" to the formulary on the same day that he had met with the drug's manufacturer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

November EMA/CHMP batch of novel medicines backed for approval
Pharmaceutical
November EMA/CHMP batch of novel medicines backed for approval
15 November 2025
Pharmaceutical
Switzerland seen as a safe haven for the life sciences
15 November 2025
Pharmaceutical
Blood thinner failure thins BMS shares
14 November 2025
Pharmaceutical
Series A extension takes TandemAI fundraising beyond $80 million
14 November 2025
Biotechnology
Terumo BCT names new head of cell and gene therapy business
14 November 2025
Biotechnology
Biokin delays Hong Kong debut as biotech sentiment cools
14 November 2025
Pharmaceutical
Hair loss pipeline looking thicker as investors plough $270 million into a cure for balding
14 November 2025

Company Spotlight

CNX Therapeutics
A speciality pharma company developing a portfolio of treatments for neurological, psychiatric and hospital emergencies.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze